Strategies for Patent Expiration and Lifecycle Management
Generic competition represents a critical issue for the pharmaceuticals industry, where the expiration of a blockbuster patent can shift over $1 billion in U.S. sales within weeks. More than $30 billion in U.S. revenues will be subject to generic challenges in the next few years. Analysis Group has assisted numerous clients with late lifecycle and post-expiry products, developing strategies for products and franchises facing generic entry, as well as models of post-expiry performance. We have assessed the impact of generic entry in the context of unique product benefits and competitive market conditions, drawing on sophisticated econometric models that take account of key product and market attributes. Our findings have led to actionable recommendations with respect to levels of product marketing and promotion and options for franchises, including authorized generics.